Today, a Director at Genomic Health (NASDAQ: GHDX), Ginger Graham, bought shares of GHDX for $285.9K.
Following this transaction Ginger Graham’s holding in the company was increased by 160.88% to a total of $1.52 million. This is Graham’s first transaction since reporting a Buy transaction on WBA back in October 2017
See today’s analyst top recommended stocks >>
Based on Genomic Health’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $95.62 million and quarterly net profit of $8.32 million. In comparison, last year the company earned revenue of $85.49 million and had a GAAP net loss of $2.74 million. GHDX’s market cap is $2.01B and the company has a P/E ratio of 517.73. Currently, Genomic Health has an average volume of 244.7K.
10 different firms, including Merrill Lynch and Canaccord Genuity, currently also have a Buy rating on the stock. Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $51.08, reflecting a 9.2% upside.
The insider sentiment on Genomic Health has been positive according to 52 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning.
